Skip to main content
Premium Trial:

Request an Annual Quote

Almac Diagnostics Opens CLIA Lab to Meet Pharma Partners' Needs

Premium

This story was originally posted on April 1.

Almac Diagnostics this week announced the opening of its US Clinical Laboratory Improvements Act-compliant laboratory.

The company, headquartered in Craigavon, Northern Ireland, said the new CLIA-registered lab supports its biomarker discovery and development services by "enabling the use of novel tests to stratify and enrich prospective clinical trials." Almac said the lab will support its own development needs as well as those of its pharmaceutical partners.

"We have come to a point where the biomarkers we have discovered and assays that we have developed are being used to stratify patients, enrich clinical trials, and impact patient treatment decisions," said Paul Harkin, president and managing director of Almac Diagnostics, in a statement. "As such, CLIA is a key necessity for the processing of these samples."

Almac offers partners a suite of Affymetrix-manufactured, Disease-Specific Arrays for breast, ovarian, colorectal, lung, and prostate cancer studies. Last year, the firm introduced its Xcel array, which contains 92,000 transcripts covering multiple disease areas and is optimized for use with formalin-fixed, paraffin-embedded tissue (BAN 6/8/2010).

Almac Diagnostics in August 2010 also launched Biomarkers for Biopharma, a menu of services specifically designed to appeal to drug developers working in the preclinical setting. Almac's Biomarkers for Biopharma services include pharmacodynamic services, markers for selecting study populations, assay development, and a bioinformatics and biostatistics consultancy (BAN 8/3/2010).

The company also has a number of tests in development. The closest to commercialization, ColDx, is for colorectal cancer recurrence. The company said last month that the test is entering its final stages of validation (BAN 3/15/2011).

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.